ArticlePsychiatric services (Washington, D.C.)2022
Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States.
Article in Psychiatric services (Washington, D.C.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review.BMC psychiatry · 2024Pooled it
- Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options.CNS drugs · 2023Pooled it
- "It's Tough to Be a Black Man with Schizophrenia": Randomized Controlled Trial of a Brief Video Intervention to Reduce Public Stigma.Schizophrenia bulletin · 2024Trial
- Commercial-Friendly Mental Health Narratives Undermine Community Mental Health: A Call for Action.Community mental health journal · 2026Article
- Perception and willingness toward second-generation long-acting antipsychotics among patients with schizophrenia: a cross-sectional survey in Fujian, China.Frontiers in psychiatry · 2026Article
- Clinical response to clozapine in Black people with psychosis: A secondary analysis of an open-label clinical trial.Therapeutic advances in psychopharmacology · 2026Article
- Gender and geographic disparities among DSM-5-TR authors in relation to financial conflicts of interest and industry payments: cross-sectional analysis.BMJ mental health · 2025Article
- Machine learning for novel phenotyping in schizophrenia.Schizophrenia research · 2025Article
- Should we be Prescribing Fluphenazine Long-Acting Injectable Formulation?Current psychiatry reports · 2025Review
- Psychiatric and racial/ethnic differences in incident and long-term benzodiazepine use: A commercial healthcare claims study.Journal of psychiatric research · 2025Article
- Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia.Neuropsychiatric disease and treatment · 2025Article
- Clozapine Use Among People With Psychotic Disorders Who Experience Specific Indications for Clozapine.The Journal of clinical psychiatry · 2024Article
- Impact of Demographics and Insurance Coverage on Schizophrenia Treatment and Healthcare Resource Utilization Within an Integrated Healthcare System.Neuropsychiatric disease and treatment · 2024Article
- Healthcare utilization and economics evaluation of paliperidone palmitate once-monthly in schizophrenia: a one-year, real-world, and retrospective mirror image study in China.Frontiers in psychiatry · 2024Article
- Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care.Neuropsychiatric disease and treatment · 2024Review
- Medical, Psychiatric, and Sociodemographic Predictors of Clozapine Initiation at an Academic Medical Center.Psychiatric research and clinical practice · 2024Article
- Predictors of Long-Acting Injectable Antipsychotic Medication Use in Patients with Schizophrenia Spectrum, Bipolar, and Other Psychotic Disorders in a US Community-based, Integrated Health System.Schizophrenia bulletin open · 2024Article
- Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects.Schizophrenia (Heidelberg, Germany) · 2023Article
- Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics-An Observational Study.Brain sciences · 2023Article
- Using focus groups to inform a brief video intervention to reduce public stigma toward Black youth living with psychosis.Frontiers in psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveVariation in prescription of psychotropic medications to patients with schizophrenia spectrum disorders may underlie health inequities. Using a national U.S. Medicaid sample, the authors examined prescription patterns of psychotropic medications commonly used for managing schizophrenia.
methodsData from the 2011-2012 Medicaid Analytic eXtract were examined for demographic predictors of and variation across states in psychotropic medication prescription among adult patients diagnosed as having schizophrenia spectrum disorders (N=357,914). Percentages of patients in each state who filled prescriptions of at least 15 days of any antipsychotic, clozapine, antidepressant, benzodiazepine, mood stabilizer, or long-acting injectable (LAI) antipsychotic medication were determined after adjustment for demographic and clinical covariates. Multivariate regressions of clinical and demographic factors predicting prescription patterns were conducted.
resultsPrescribing patterns for all types of psychotropic medications varied across states. Clozapine and LAI prescriptions showed the most dramatic differences across states and among patients with different demographic characteristics. Across states, adjusted proportions of prescriptions ranged from 4% to 22% for LAIs and from 1% to 11% for clozapine. Non-Hispanic Blacks and people of other race-ethnicities were more likely than non-Hispanic Whites to fill prescriptions for LAIs, and non-Hispanic Whites were more likely than individuals from other racial-ethnic groups to fill prescriptions for clozapine and all other medications.
conclusionsConsiderable variation in prescribing patterns of LAIs and clozapine by race-ethnicity and across states suggests uneven quality of care for individuals with schizophrenia spectrum disorders in the United States. A better understanding of what causes this variation could inform policy makers to improve treatment for this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.